Nkarta, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. Filed March 17, 2022. This is an annual report, not a standalone fourth-quarter report. Nkarta is a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer cell therapies. It had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $63.4 million | $36.2 million |
| General and administrative expense | $23.0 million | $15.3 million |
| Total operating expenses / operating loss | $86.4 million | $51.5 million |
| Net loss | $86.1 million | $91.4 million |
| Net loss per share, basic and diluted | $2.62 | $5.44 |
| Net cash used in operating activities | $67.9 million | $43.5 million |
- At year-end, cash and cash equivalents were $60.8 million, short-term investments were $177.3 million, and restricted cash was $2.1 million: $240.2 million combined. Total assets were $273.9 million.
- Total liabilities were $22.9 million, including $12.5 million of recognized operating lease liabilities. The filing reports no material conventional debt balance.
- Management said available cash, cash equivalents, restricted cash, and short-term investments were expected to fund operations for at least 12 months from the filing date. It also warned that forecasts are uncertain and additional funding will be needed.
- Margins are not meaningful because the company had no product revenue. No formal financial guidance was provided.
Material changes and notable items
- R&D expense rose 75% year over year, primarily from higher personnel costs and increased clinical and external program costs for NKX101 and NKX019. G&A expense also increased, reflecting headcount, professional services, insurance, and facility costs.
- Operating cash use increased to $67.9 million from $43.5 million. Net loss nevertheless narrowed, mainly because FY2020 included a $40.2 million noncash charge from remeasuring a preferred-stock purchase-right liability; that liability was settled in 2020.
- Investing activities provided $32.5 million in 2021, chiefly from maturities of short-term investments, partly offset by purchases of investments and property and equipment.
- Nkarta signed a lease for an 88,000-square-foot South San Francisco facility, with approximately $99.6 million of base rent expected over the lease term. The lease commenced for accounting purposes in January 2022; the company expected to record approximately $49–$62 million of lease liabilities and corresponding right-of-use assets. A separate lease amendment carries about $4.6 million of expected base rent.
Pipeline, outlook, and key risks
- NKX101: Ongoing Phase 1 trial for relapsed/refractory AML and higher-risk MDS. The FDA granted orphan drug designation for AML. Management expected initial dose-finding data in the first half of 2022 and planned a solid-tumor program, subject to development progress.
- NKX019: Phase 1 trial for B-cell malignancies began dosing in October 2021. Management expected initial dose-finding data in 2022.
- CRISPR collaboration: Research programs include gene-edited CD70 CAR-NK and NK+T candidates. The parties share research and development costs and potential profits on collaboration products. No milestones had been achieved by year-end.
- Management expected operating expenses to increase as clinical programs advance, research expands, and manufacturing capacity is developed. The company had a 2,700-square-foot clinical cGMP facility and was designing the larger facility for future pivotal-trial and potential commercial supply. The stated approximately $2,000-per-dose manufacturing cost is a company estimate based on specified scale and assumptions, not demonstrated commercial economics.
- Key risks include early-stage clinical uncertainty, trial enrollment and safety outcomes, manufacturing scale-up and regulatory qualification, COVID-19-related supply and site disruptions, and reliance on third parties. The company also disclosed reliance on Miltenyi as sole supplier for certain manufacturing equipment and reagents.
- Other notable exposure: third parties had requested reexamination of two licensed patents related to NKX101. Management reported no pending legal claims it considered likely to have a material adverse effect.
Important facts for investors to verify
- Whether NKX101 and NKX019 produce meaningful clinical safety, response, and durability data, and whether timelines or protocols changed after the filing.
- Actual cash runway and subsequent financing activity, including use of the $150 million at-the-market program; no ATM sales had occurred as of December 31, 2021.
- Progress, costs, and timing for the new manufacturing facility, including the substantial lease commitments and the expected lease accounting.
- Whether manufacturing yields, cryopreserved product performance, and the estimated per-dose cost hold at larger scale; the filing does not establish commercial-scale performance.
- Any material developments in COVID-related supply or trial disruption, Miltenyi supply continuity, CRISPR collaboration programs, or the patent reexaminations.